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Abstract
Background: Bone morphogenetic proteins (BMP) are embryonic proteins that are part of the transforming growth
factor (TGFβ) superfamily, which are aberrantly expressed in many carcinomas. Inhibition of BMP receptors with small
molecule inhibitors decreases growth and induces death of lung cancer cells, which involves the downregulation of
Id1 and Id3 by a Smad dependent mechanism. Developmentally, BMP and TGFβ signaling utilizes Smad-1/5
independent mechanisms to stabilize the expression of X-linked inhibitor of apoptosis protein (XIAP) and activate TGFβ
activated kinase 1 (TAK1), which are known to be potent inhibitors of apoptosis. The role of BMP signaling in regulating
XIAP and TAK1 in cancer cells is poorly understood. Furthermore, the interaction between the BMP and TGFβ signaling
cascades in regulating the activation of TAK1 in cancer cells has not been elucidated.
Methods: Feedback regulation between the BMP and TGFβ signaling pathways and their regulation of XIAP, TAK1, and
Id1 were examined in lung cancer cells utilizing siRNA and inhibitors targeting BMP type I receptors, inhibitors of BMP
and TGFβ type I receptors, and an inhibitor of BMP and TGFβ type I and type II receptors.
Results: We show that upon inhibition of BMP signaling in lung cancer cells, the TGFβ signaling cascade is activated.
Both the BMP and TGFβ pathways activate TAK1, which then increases the expression of Id1. Inhibition of TGFβ
signaling increased Id1 expression except when BMP signaling is suppressed, which then causes a dose-related
decrease in the expression of Id1. Inhibition of both BMP and TGFβ signaling enhances the downregulation of TAK1.
Our data also suggests that the blockade of the BMP type II receptor enhances the downregulation XIAP, which is
important in decreasing the activity of TAK1. Knockdown studies demonstrate that both XIAP and TAK1 regulate the
survival of lung cancer cells.
Conclusions: This paper highlights that targeting the BMP and TGFβ type I and type II receptors causes a
downregulation of XIAP, TAK1, and Id1 leading to cell death of lung cancer cells. Small molecule inhibitors targeting
the BMP and TGFβ receptors represents a potential novel means to treat cancer patients.
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Background
Lung cancer is the leading cause of cancer deaths in the
United States. An estimated 185,000 people are expected
to die this year in the United States from lung cancer.
More patients succumb to lung cancer than breast,
colon, and prostate cancer combined. Despite advances
in medical care, 85 % of patients diagnosed with lung
cancer will die from their disease. It is clear from these
dismal statistics that novel therapeutic targets and treat-
ment strategies are needed for the treatment of lung
cancer.
Bone Morphogenetic proteins (BMP) are members of
the Transforming Growth Factor superfamily (TGFβ).
BMP2 and BMP4 are phytogenetically conserved mor-
phogens required for embryonic development across
species from insects to humans [1, 2]. Upon completion
of lung morphogenesis BMP signaling is barely detect-
able in normal adult lung tissue [2]. BMP signaling is
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reactivated in lung injury and non-small cell lung
(NSCLC) and small cell carcinomas [3, 4]. BMP2 expres-
sion is highly over-expressed in 98 % of NSCLC com-
pared to normal lung tissue and benign lung tumors [3].
The activation of BMP signaling has been implicated in
the tumorigenesis of lung and many other carcinomas.
BMP2 induces tumor angiogenesis [5], stimulates the
migration [4] and metastasis of cancer cells [6, 7], and
its expression is associated with a worse prognosis [8].
Approximately 20 BMP ligands have been identified
and categorized into several subclasses. BMPs signal
through transmembrane serine/threonine kinases com-
posed of type I and type II receptors. The type I recep-
tors are ALK1, ALK2 (ActR-1), ALK3 (BMPR-IA), and
ALK6 (BMPR-IB) [9]. The type II receptors are BMPR-II
and activin type II receptors ActR-II and AcR-IIB [9].
Each BMP receptor can be activated by several different
BMP ligands [9]. Binding of the BMP ligand to the type
I receptor leads to phosphorylation by the constitutively
active type II receptor. This receptor complex then
phosphorylates Smad-1/5 [10] and activates the tran-
scription of downstream target genes including inhibitor
of differentiation proteins (Id1, Id2, and Id3) through
BMP response elements on their promoter [11–15].
Recent studies have demonstrated that the BMP sig-
naling cascade promotes growth and survival of lung
cancer cells [16]. Downregulation of the type I BMP re-
ceptors with siRNA or small molecule inhibitors
(DMH2, DMH1) in lung cancer cells caused growth in-
hibition and cell death, which is associated with a down-
regulation of Id1 and Id3 [16]. Knockdown of either Id1
or Id3 also suppressed growth and induced cell death
[16]. Forced expression of Id3 attenuated growth sup-
pression and cell death caused by BMP receptor inhibi-
tors [16]. These studies demonstrate that the BMP
signaling cascade promotes tumorigenesis that involves a
Smad 1/5 dependent regulation of Id1-Id3. This report
also highlighted that small molecule inhibitors of the
BMP receptors can be used to interrogate the BMP sig-
naling cascade in cancer cells and represents a potential
therapeutic strategy for the treatment of lung and other
cancers.
The regulation of Id proteins by the BMP signaling
cascade has important therapeutic implications. There
are numerous reports demonstrating the importance of
Id proteins promoting tumorigenisis in many types of
cancers. Expression of Id proteins by immortalize cells
stimulate tumor invasion and metastasis and are essen-
tial for tumor angiogenesis. The expression of Id1 is ne-
cessary for Ras induced tumor formation by inhibiting
senescence [17]. There are limited data demonstrating
other signaling pathways that are direct transcriptional
regulators of Id proteins. Scr is reported to enhance the
transcription of Id1 by binding the BMP transcriptions
factors Smad-1/5, which promotes its translocation into
the nucleus and activation of the Id1 promoter [18]. One
report suggested mitogen-activated protein kinases
(MEK-1/2) may promote the transcription of the Id1
promoter through its regulation of the early growth re-
sponse protein (Egr-1) [19]. The TGFβ signaling cas-
cade acts predominately to decrease the expression of
Id1 [20, 21]. In some cells, TGFβ signaling has been
shown to increase the transcription of Id1 [22]. Dur-
ing development, the BMP signaling cascade sup-
presses (MEK-1/2) activity to promote self-renewal of
mouse embryonic stem cells [23]. The BMP pathway
(Scheme 1) has also been shown to regulate the ex-
pression of Src through its interaction with the
BMPRII [24]. These studies highlight the potential for
feedback regulation between the BMP, Scr, TGFβ,
and/or MEK-1/2 effecting the transcription of Id pro-
teins thereby affecting the potency of BMP receptor
inhibitors.
Through evolutionary conserved pathways, the BMP
signaling cascade also regulates embryonic development
through Smad-1/5 independent mechanisms. The activa-
tion of TGFβ activated kinase 1 (TAK1) by the BMP sig-
naling cascade is required for ventralization of embryos
[25]. The BMP signaling cascade regulates TAK1 by in-
creasing the expression of x-linked inhibitor of apoptosis
protein (XIAP) through its binding to the cytoplasmic do-
mains of the type I and type II BMP receptors [26]. XIAP
binds TAK1-binding protein (TAB1) that recruits TAK1
leading to its activation [25]. Both the TGFβ and BMP sig-
naling cascades induce the activation of TAK1 and
stabilize the expression of XIAP. TAK1 can induce a feed-
forward activation of BMP signaling by phosphorylating
Smad 1/5 [27]. TAK1 and XIAP are potent inhibitors of
apoptotic cell death in cancer cells [28, 29]. The regulation
of XIAP and TAK1 by the BMP signaling cascade in can-
cer cells is poorly elucidated. It is also not known whether
the expression of XIAP and activity of TAK1 is regulated
by BMP receptor inhibitors. The one report examining
BMP regulation of XIAP in cancer cells showed that
BMPRII in osteosarcoma cell lines stabilized the expres-
sion of XIAP [30]. Furthermore, it is not known whether
the BMP and TGFβ signaling cascades cooperate to regu-
late XIAP and TAK1 in cancer cells.
Using inhibitors blocking the activity of specific type I
and type II BMP and TGFβ receptors together with RNAi
knockdowns, we examined the mechanisms by which the
blockade of the BMP receptors regulates survival of lung
cancer cells. We found that suppression of BMP signaling
results in feedback activation of the TGFβ signaling, which
gives rise to the activation of TAK1. BMPRII regulates the
expression of XIAP in lung cancer cells, which activates
TAK1. We demonstrate that a small molecule inhibitor of
BMP receptors downregulates the expression of XIAP and
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TAK1 in lung cancer cells. We provide evidence support-
ing that an inhibitor targeting the BMP and TGFβ type I
and type II receptors will result in the greatest downregu-
lation of Id1, TAK1, and XIAP and induction of apoptotic
cell death of lung cancer cells. This paper provides a
mechanistic rational directing further drug development
to target the BMP/TGFβ signaling cascades for the treat-
ment of cancer.
Results
DMH2 inhibits the expression of Id1 and growth of
different types of lung cancer cells
To better understand the role of BMP inhibitors to treat
lung cancers, the potency of the BMP receptor inhibitor,
DMH2 [16, 31], to decrease the expression of Id1 and its
effect on cell growth was examined in a panel of lung
cancer cell lines of different cell types and mutations
commonly found in lung cancer. The lung cancer cell
lines examined consisted of a squamous carcinoma
(H157), adenocarcinoma (A549), poorly differentiated
carcinoma (H1299), low-grade (H727) and high-grade
(U1752) neuroendocrine carcinomas. The mutations in-
cluded a p53 deletion (H1299), activating K-Ras muta-
tions (A549, H157, H727), and PNET deletion (H157).
DMH2 decreased the expression of Id1 (Additional file
1: Figure S1A) and inhibited growth in all of the cell
lines (Additional file 1: Figure S1B). These studies
suggest that inhibition of BMP signaling may have
significant anti-tumor effects across a broad range of
lung carcinomas.
BMP Inhibitors increase expression of Id1 in tumor
xenografts
The effect of the BMP receptor inhibitors DMH2 and
LDN-193189 (LDN) [32] to regulate Id1 expression in
tumor xenografts was examined. Established xenografts
from H1299 cells stably expressing an Id1 promoter
regulating luciferase were treated with DMH2 or LDN
Scheme 1 BMP pathway
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and tumor luminescence was measured before and after
treatment. Tumor luminescence was increased at 4 h,
24 h, and 48 h following treatment compared to baseline
with the greatest effect seen at 24 h (Fig. 1a–d). In total,
13 of 17 mice treated with a BMP inhibitor showed an
increase in Id1 promoter activity in the tumor (Fig. 1a–
d). Immunoblot analysis demonstrated a 27 % increase
in ID1 expression in xenografts treated with BMP inhibi-
tors for 24 h as compared to controls (Fig. 1e and f). At
9 days following treatment with DMH2 there was a
103 % increase in the expression of Id1 protein com-
pared to controls (Fig. 1g and h). We examined in vitro
the dose responsive regulation of Id1 in H1299 and
A549 cells following treatment with DMH2 for 24 and
48 h. These studies showed that low doses of DMH2 as
low as 0.5 μM can cause an increase in the expression of
Id1 followed by suppression of Id1 expression at higher
concentrations (Fig. 1i and j, Additional file 2: Figure
S2). In the study for the H1299 cells, we found a de-
crease in Id1 expression followed by an increase and
complete suppression at higher doses. These studies are
consistent with BMP inhibition leading to feedback acti-
vation of Id1 expression with lower concentration of
BMP inhibitor.
Pharmacokinetics of DMH2
We next examined the bioavailability of DMH2. The
percent of DMH2 binding plasma proteins in human
and mouse plasma is 98.6 % +/−0.7 and 98.2 % +/−1.5
respectively. DMH2 exhibited moderate to high systemic
plasma clearance (68.45 mL/min/kg) with elimination
half-life of 0.95 h (Additional file 2: Figure S2A). LDN is
reported to have an elimination half-life of 90 min in
mice [32]. The IC50 of DMH2 for the BMP type I recep-
tor Alk2 is reported to be 42.8 nM [31]. Therefore, the
free fraction of unbound DMH2 above its IC50 for Alk2
is less than 25 min (Additional file 3: Figure S3B). These
pharmacokinetic studies suggest that DMH2 would pro-
vide only weak inhibition of BMP signaling in tumor xe-
nografts. These studies suggested that DMH2 might be a
weak inhibitor in vivo, which allows other signaling
pathways to regulate the transcription of Id1.
MEK-1/2 and Src do not cause feed-back activation of Id1
To assess potential activated feedback loops following
inhibition of BMP signaling, we examined the pathways
reported to regulate the transcription of Id1. Src was not
activated in tumors treated with BMP inhibitors for 24 h
or 9 days. Although inconsistent, some of the tumors
treated with BMP receptor inhibitors had an increase in
the expression of phosphorylated MEK-1/2 (Additional
file 3: Figure S3A and B). In vitro, DMH2 caused an in-
crease in the expression of phosphorylated MEK-1/2 in
H1299 (Additional file 3: Figure S3C) and A549 cells
(Additional file 4: Figure S4D). We examined whether
Egr-1, the transcriptional regulator of Id1 induced by
pMEK-1/2, was regulated following BMP inhibition. We
found no change in the expression of Egr-1 with the ac-
tivation of MEK-1/2, suggesting MEK-1/2 did not regu-
late Egr-1 in the H1299 cells (Additional file 4: Figure
S4C). The activation of MEK-1/2 corresponded with a
decrease in the expression of Id1 (Additional file 4: Fig-
ure S4D and Additional file 1: Figure S1J) and not an in-
crease as would be expected if it where activating the
transcription of Id1. The specific MEK-1/2 inhibitor
PD0325901 (PD) [33] did not regulate the promoter ac-
tivity of Id1 as demonstrated in the Id-1 luciferase re-
porter assay in H1299 cells (Additional file 4: Figure
S4E). Furthermore, PD when combined with DMH2 had
no additional effects on growth inhibition of H1299 and
A549 cells compared to DMH2 alone (Additional file 4:
Figure S4F-G). These studies support that Scr and MEK-
1/2/Egr-1 signaling pathways were not the mechanism
causing the increase in Id1 expression following low
levels of inhibition of BMP signaling.
Suppression of BMP signaling results in activation of
TAK1 and TGFβ
Since both the BMP and TGFβ signaling cascades regu-
late TAK1, which has been shown to cause a feed-
forward activation of BMP signaling in cartilage progeni-
tor cells [34], we next examined the activation of TAK1
and TGFβ following the suppression of BMP signaling.
Tumor xenografts treated with DMH2 for 24 h and
9 days showed activation of TAK1 and TGFβ signaling
as demonstrated by an increase in phosphorylated TAK1
and Smad2 respectively (Fig. 2a and b). In vitro, DMH2
caused an increase in phosphorylation of TAK1and
Smad2 at lower doses, which tapered off at higher doses
(Fig. 2c and d). The decrease in activity of Smad2 corre-
sponded with a significant decrease in the expression of
Id1 in both H1299 and A549 cells (Fig. 1j and Additional
file 3: Figure S3D). The unphosphorylated Smad2 was
regulated in a similar fashion except that its downregula-
tion occurred at a higher concentration than pSmad2
(Fig. 2c and d). Knockdown of the BMP type I receptors
alk2 and alk3 as well as alk2, alk3, and alk6 caused an
increase in expression of Smad2 and pSmad2 (Fig. 2e).
DMH1, an inhibitor specific for BMP type I receptors
with no activity for TGFβ receptors [31], also caused the
activation of Smad2 and TAK1 (Fig. 2f ). Unlike DMH2
that inhibits the TGFβ type I receptor Alk5 [31], DMH1
did not decrease the expression of Smad2 or pTAK at
higher doses. These studies show that suppression of
BMP signaling results in a feed-back increase in the
expression and activation of Smad2 and TAK1. These
studies also demonstrated a functional difference be-
tween the BMP inhibitors DMH1 and DMH2.
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Fig. 1 (See legend on next page.)
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DMH2 is more potent than DMH1 and has a different
IC50 profile
We previously reported that DMH2 causes a greater de-
crease in the expression of Id1 protein and cell growth
in comparison to DMH1 [16]. To better understand dif-
ferences between DMH1 and DMH2, we determined the
IC50 of DMH2 for all the BMP type I receptors, Alk5, as
well as BMPRII and TGFβ type II receptors and com-
pared it to the reported literature for DMH1 and LDN
(Table 1) [35]. Both DMH1 and DMH2 inhibited Alk2
and Alk3 at nanomolar concentrations. DMH2 inhibited
Alk5 at an IC50 of 1690 nM, which would account for
the decrease in pSmad2 expression at 2.5 μM (Fig. 2c
and d). Unique to DMH2 was the inhibition of BMPRII,
which does not occur with DMH1 or LDN (Table 1).
DMH2 causes significantly greater suppression of Id1
promoter activity at 1.0 μM and 2.5 μM in the H1299
cells in comparison to DMH1 (Additional file 5: Figure
S5). We also found that DMH2 induces significantly
greater growth suppression and cell death of H1299 cells
compared to DMH1 and LDN (Additional files: Figure
S6 and Figure S5). These data suggest that the inhibition
of both the BMP and TGFβ signaling cascades may en-
hance the downregulation of Id1 leading to greater
growth inhibition and cell death.
TAK1 activates BMP signaling
We next examined whether TAK1 causes a feed-forward
activation of BMP signaling in lung cancer cells and
whether both the BMP and TGFβ signaling pathways ac-
tivated TAK1. Transient expression of constitutively ac-
tive BMP and TGFβ type I receptors caused the
activation of TAK1 and Id1 expression in the H1299
cells (Fig. 3a and b), confirming their role in activating
TAK1 in our lung cancer cells. The irreversible TAK1 in-
hibitor, 5Z-7-oxozeaenol (5Z) [36], causes a dose-related
decrease in the expression of pSmad 1/5, Id1, and
pTAK1 after 24 h (Fig. 3c). After 24 h, 2 μM of 5Z also
suppressed Id1 promoter activity (Fig. 3d). Interestingly,
after 48 h 5Z had the opposite effect, now increasing the
expression of Id1, pSmad 1/5, and pTAK1, and no
longer suppressed the Id1 promoter (Fig. 3e and f),
demonstrating that 5Z induces feedback activation of its
intended target. Furthermore, the combination of 5Z
and DMH2 also did not enhance growth suppression
(Fig. 3f–h). These data suggest that activated TAK1
stimulates Smad 1/5-Id1 signaling through a feed-
forward mechanism in lung cancer cells.
TGFβ signaling increases Id1 expression by activating TAK
We next examined TGFβ regulation of TAK1 and Id1
using the highly specific TGFβ antagonist SB-505124
(SB) [37] alone and in H1299 cells in which BMP signal-
ing was suppressed with low dose of DMH2. SB alone
caused a dose-related increase in the expression of Id1,
suggesting TGFβ suppressed Id1 expression in H1299
cells (Fig. 4a). When BMP signaling was suppressed, SB
had the opposite effect, now causing a dose-related de-
crease in the expression of Id1 (Fig. 4a). TGFβ signaling
is reported to increase the expression ATF3, which is a
co-repressor required for Smad3 to suppress the Id1
promoter [21]. In the absence of ATF3, Smad3 can acti-
vate the transcription of Id1. There were no significant
change in the expression of ATF3 following suppression
of BMP and TGFβ signaling, suggesting that ATF3 was
not involved in the change of Id1 expression (Fig. 4a).
SB alone caused an increase in the Id1 promoter activity
in H1299 cells (Fig. 4b). When BMP signaling was sup-
pressed with a low dose of DMH2, SB again had the op-
posite effect, now causing a dose-related decrease in Id1
promoter activity (Fig. 4b). We next asked whether inhi-
biting the feed-back activation of TGFβ signaling would
enhance DMH2 downregulation of Id proteins and
pTAK1. DMH2 caused a greater downregulation of the
expression of Id1 and Id3 when used in combination
with SB compared to DMH2 alone (Fig. 4c). In addition,
there was a greater decrease in the expression of pTAK1
when DMH2 and SB were used in combination (Fig. 4c).
To further examine the role of TGFβ signaling causing
a feedback activation of the BMP-TAK1-Id1 signaling
cascade, H1299 cells were transiently transfected with
vector control or constitutively active Alk5 (caAlk5) and
treated with 0.1 and 0.5 μM of DMH2 for 48 h. Low
doses of DMH2 were used so as not to inhibit TGFβ
(See figure on previous page.)
Fig. 1 DMH2 causes an increase in Id1 expression in tumor xenografts and in vitro at low concentrations. a Mice with established tumors from
H1299 Id-luc cells were treated with DMSO or 3 mg/kg of DMH2 or 3 mg/kg LDN and after 4 h tumor luminescence determined and compared
to baseline (n = 3 for each group). (b) Two days later mice were treated with DMSO or 3 mg/kg of DMH2 or 3 mg/kg LDN every 8 h for 24 h and
tumor luminescence determined and compared to baseline. (c) In a separate experiment, established tumors were treated with DMSO (n = 3) or
3 mg/kg of DMH2 (n = 5) twice daily for 48 h and luminescence was compared to baseline. (d) Bioluminescence images of H1299 Id1-luc tumors
before and after treatment with BMP inhibitors for 24 h. Data depicted as fold increase in tumor luminescence of mice treated with inhibitors
compared to baseline. (e) Western blot analysis of tumor xenografts from mice treated with DMSO or 3 mg/kg of DMH2 or 3 mg/kg LDN every
8 h for 24 h and (f) the mean optical density readings of Id1 from the corresponding Western blot was normalized to GAPDH and presented as
percent of control. (g) Western blot analysis of xenografts from mice treated with twice-daily injection of DMH2 for 9 days and (h) the mean
optical density readings of Id1 from the corresponding Western blot was normalized to GAPDH and presented as percent of control. (i, j) Western
blot analysis of H1299 cells in cell culture treated with increasing doses of DMH2 for 24 (n = 2) (i) and (j) 48 h (n = 4)
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signaling. When BMP signaling was inhibited by
DMH2, caAlk5 enhanced the activation of TAK1 and
Id1 expression compared to cells treated with DMH2
alone (Fig. 4d). The increase in expression of Id1
and pTAK1 induced by caAlk5 together with 0.5 μM
of DMH2 was antagonized by a 24-h treatment with
5Z (Fig. 4d). These studies support our observation
that when BMP signaling is attenuated, activation of
TGFβ signaling increases Id1 expression by activat-
ing TAK1.
Antagonizing both BMP and TGFβ signaling enhances
growth suppression
If inhibiting both BMP and TGFβ signaling enhances the
downregulation of Id1, we would expect to have greater
growth suppression when both were used together. We
examined whether suppressing both BMP and TGFβ sig-
naling enhanced growth suppression by treating cells
with a BMP receptor inhibitor alone or in combination
with SB. DMH2 alone caused significant growth sup-
pression of the H1299 (Additional file 6: Figure S6A).
Fig. 2 Inhibition of BMP signaling activates TAK1 and Smad2. a, b Western Blot analysis of H1299 tumor xenografts treated with DMH2 for 24 h
and 9 days showing inhibitors increase expression of pSmad2 and pTAK1. (c, d) Western blot analysis of H1299 and A549 cells treated with
increasing doses of DMH2 in vitro for 48 h showing an increase followed by a decrease in expression pTAK1 and pSmad2 (n = 4). (e) Western blot
of knockdown of alk2 and alk3 or alk2, alk3, and alk6 showing an increase in pSmad2 and Smad2 expression (n = 2). (f) Western blot of cells
treated with DMH1 in vitro for 48 h (n = 3)
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The combination of DMH2 and SB caused a signifi-
cantly greater decrease in cell number compared to
either drug alone (Additional file 6: Figure S6A). SB
alone had little effect on the growth of the H1299
cells (Additional file 6: Figure S6A). In the A549 cells,
both DMH2 and SB-505124 alone caused growth sup-
pression (Additional file 6: Figure S6B). A549 cells
treated with both 2.5 μM DMH2 and 2.0 μM SB had
significantly fewer cells than either compound alone
(Additional file 6: Figure S6B). 2.5 μM of DMH1
combined with 1.0 μM or 2.0 μM SB-505124 caused
significantly greater growth suppression than either
compound alone (Additional file 6: Figure S6D).
DMH2 induction of cell death involves the
downregulation of pTAK1
We next examined if the regulation of TAK1 was a
mechanism by which BMP inhibitors induced death of
lung cancer cells. DMH2 induced expression of activated
caspase-3 at 48 h (Fig. 5a and b) and by 72 h cells
showed significant shrinkage and chromatin condensa-
tion (Fig. 5c). These studies support our observation that
DMH2 induces apoptotic cell death. DMH2 induced sig-
nificant cells death of H1299 and A549 cells after 3 days
(Fig. 5d and e). The addition of SB together with DMH2
did not cause further cell death (Fig. 5d and e). Examin-
ing the mechanisms by which DMH2 induces cell death,
we found that DMH2 caused a very significant decrease
in the expression of Smad2 in both H1299 and A549
cells (Fig. 5f and g). This was associated with a decrease
in expression of TAK1 and the phosphorylation of its
downstream target the NF-kappa B subunit p65 [28]
(Fig. 5f and g). Knockdown of TAK1 with siRNA in the
H1299 cells caused cell death suggesting its downregula-
tion is a mechanism by which DMH2 induces cell death
(Fig. 5h and i). DMH1 (2.5 μM) alone or when combined
with SB caused little cell death in comparison to DMH2
(Fig. 5j). DMH1 alone or in combination with SB also
Fig. 3 BMP and TGFβ signaling activates TAK1 which stimulates BMP signaling. a, b Western blot analysis showing that transient expression of
constitutively active alk3, alk6, or alk5 increases expression of pTAK1 (n = 3). (c-f) TAK1 antagonist 5Z-7-oxozeaenol (5z) decreases BMP signaling
after 24 h but increases it at 48 h (n = 3). (c) Western blot analysis and (d) Id1-luciferase assay of H1299 cells treated with 5z for 24 h. (e) Western
blot analysis and (f) Id1-luciferase assay of H1299 cells treated with 5z and DMH2 for 48 h. (g, h) H1299 cells were treated with DMH2 or 5Z-7-
oxozeaenol (5Z-7) alone, and in combination for 7 days and the number of live cells determined. Data in growth assays were depicted as the
percent of the DMSO control. All studies were performed at least 3 times
Table 1 IC50
Half maximal inhibitory concentration (IC50)
Alk2/ACVRR1(nM) Alk3/BMPR1A(nM) Alk6/BMPRII(nM) BMPRII(nM) Alk5/TGFbetaR1(nM) TGFbetaR2(nM)
DMH2 23 92 43 7,950 1,690 193
DMH1 108 5 – – – – (35)(35)
LDN 5 20 3 – 185 151
Inhibition of kinase activity of BMP and TGF beta receptors was determined for DMH2 and compared to DMH1 and LDN
Augeri et al. Molecular Cancer  (2016) 15:27 Page 8 of 16
did not activate caspase-3 or downregulate Smad2,
pTAK1, or p-p65 after 3 days (Fig. 5k and l). LDN is an
inhibitor of both the BMP and TGFβ receptors. LDN
also caused little cell death and downregulation of
Smad2 and TAK1 in comparison to DMH2 after 3 days
(Fig. 5m and n). These studies supports that DMH2
downregulation of TAK1 is involved in induction of cell
death but that additional mechanism(s) may also be in-
volved in addition to inhibition of BMP type I receptors
and TGFβ signaling.
DMH2 induction of cell death involves XIAP, which
regulates the activity of TAK1
During embryonic development the BMP signaling
cascade mediates the activation of TAK1 by stabiliz-
ing the expression of XIAP through Smad1/5 inde-
pendent mechanism [38]. DMH2 caused a significant
decrease in the expression of XIAP in both the
H1299 and A549 cells after 3 days (Fig. 6a and b).
LDN and DMH1 alone or with SB-505124 did not
downregulate the expression of XIAP after 3 days
(Fig. 6c and d). Knockdown of XIAP with siRNA in
the H1299 cells induced cell death (Fig. 6e) and
caused a decrease in expression of pTAK1 (Fig. 6f ).
Since BMP type I and type II regulate the ubiquiti-
nation of XIAP [26], mutant XIAP that has had its
lysine ubiquitination sites mutated [39] was transi-
ently transfected into the H1299 cells. H1299 cells
expressing mutant XIAP had a higher expression of
pTAK1 compared to vector control cells (Fig. 6g).
DMH2 decreased the expression of Id1 and wild
type XIAP but not the mutant XIAP (Fig. 6h). Mu-
tant XIAP and vector control cDNA were stably
transfected into the H1299 cells. H1299 cells ex-
pressing mutant XIAP were resistant to cell death
induced by DMH2 (Fig. 6i). In cells stably expressing
mutant XIAP, DMH2 also decreased the expression
of wild type XIAP but not mutant XIAP (Fig. 6j).
These studies show that XIAP is an upstream regula-
tor of TAK1 in lung cancer cells and that the down-
regulation of XIAP is required for DMH2 induced
cell death.
Fig. 4 Inhibition of both BMP and TGFβ signaling enhances the downregulation of pTAK1 and Id1. a Western blot analysis of H1299 cells treated with
increasing doses of the TGFβ inhibitor SB-505124 (SB) with and without DMH2. SB and DMH2 together enhanced the downregulation of Id1 (n = 3).
(b) Id1-luciferase assay demonstrating decreased Id1 promoter activity only in cells treated with both SB and DMH2 (n = 2). (c) Western blot analysis of
H1299 cells treated with 1 μM SB and increasing doses of DMH2 (n = 4). The combination of SB and DMH2 enhanced the downregulation of Id1, Id3,
and pTAK1. (d) H1299 cells were transfected with constitutively active alk5 (ca alk5) or empty vector and treated with DMSO or DMH2 for 48 h (n = 3).
Cells were also treated with or without 2 μM 5z for 24 h. Western blot shows that when BMP signaling is inhibited caAlk5 increases Id1 and pTAK1
expression that is attenuated with 5z. Arrows show increased expression of Id1 and pTAK1 in cells treated with caAlk5 and DMH2 compared
to controls
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Inhibition of BMP type I receptors and TGFβ signaling
induce cell death when XIAP is downregulated
To further examine the role of the TGFβ signaling cas-
cade in regulating cell death, XIAP was knocked-down
in H1299 cells then cells were treated with the inhibitor
of the BMP type I receptors (DMH1) and with the TGFβ
antagonist LY2109761 (LY) [40]. The greatest cell death
and decrease in pTAK1 expression occurred in XIAP
knockdown cells treated with a combination of DMH1
and LY (Fig. 7a and b). These data further support that
the downregulation of XIAP and inhibition of TGFβ sig-
naling are mechanisms by which DMH2 inhibits TAK1
and induces cell death.
BMPRII regulates XIAP expression
Since DMH2 inhibits BMPRII (Table 1), we examined
whether the downregulation of BMPRII effects the ex-
pression of XIAP in lung cancer cells. The knockdown
of BMPRII by siRNA decreased the expression of XIAP
in the H1299 cells (Fig. 7c). These data suggest that
Fig. 5 DMH2 induction of cell death involves the downregulation of pTAK1. a, b Western blot of H1299 and A549 cells treated with DMH2 for 48 h
demonstrating an increase in activated caspase-3. (c) Representative images of H1299 cells treated with 1 μ DMH2 for 3 days demonstrating significant
cell shrinkage and chromatin condensation. (d, e) H1299 and A549 cells were treated with DMH2 alone or in combination with SB for 3 days and cell
death was determined. (f, g) Western blot analysis of cells treated with DMH2 or SB for 3 days. (h) Knockdown of TAK1 was performed in H1299 cells
using siRNA. The percentage of dead cells was determined after 3 days. (i) Western blot analysis showing knockdown of TAK1 in H1299
cells. (j, k) DMH1 alone or in combination with SB did not cause significant cell death in H1299 cells after 3 days (k) and did not induce
the activation of caspase-3. (l) Western blot analysis demonstrating DMH1 alone or in combination with SB did not show significant regulation of
Smad2, pTAK1, or p65. (m) LDN induced little cell death compared to DMH2 and (n) did not downregulate Smad2 or TAK1 by Western blot analysis.
All experiments were performed at least 3 times
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DMH2 inhibition of BMPRII is an important mechanism
by which it decreases the expression of XIAP and induces
cell death in cancer cells. Scheme 1 demonstrates the
interactive pathways mediated by the BMP and TGFβ
signaling pathways to regulate survival of cancer cells.
Discussion
The BMP signaling pathway is a potent direct regulator of
the transcription of Id1, Id2, and Id3 during development
as well as in cancer cells [11–16]. The decrease in the ex-
pression of Id proteins is an importance mechanism by
which BMP inhibitors regulate anti-tumor effects [16].
Numerous studies have demonstrated the importance of
Id proteins in cancer by regulating invasion, metastasis,
angiogenesis, cell growth and survival [4, 14, 41–43]. Sur-
prisingly, our xenograft studies showed that DMH2
caused an increase in the expression of Id1. The increase
in the expression of the Id1-luciferase reporter was con-
sistent with a feedback loop activating the Id1 promoter.
The poor pharmacokinetics of DMH2 with high plasma
protein binding and rapid clearance suggest that DMH2
would have provided only weak inhibition in tumor xeno-
grafts. Our studies suggested that with low levels of inhib-
ition of BMP signaling, feedback loops activated the
transcription of Id1. Our studies support that the feedback
activation of Id1 upon inhibition of BMP signaling did not
occur through the Src or MEK-1/2 signaling pathways.
We found that the inhibition of BMP signaling in lung
cancer cells causes an increase in the expression of acti-
vated TAK1 and TGFβ. TAK1 has been shown to cause
a feedforward activation of BMP signaling in progenitor
cells by binding to Smad-1/5 [27]. We show that TAK1
also activates pSmad-1/5 and increases the expression of
Id1 in lung cancer cells. Consistent to reported literature
Fig. 6 DMH2 regulation of cell death involves the downregulation of XIAP, which regulates the activity of TAK1. a-d Western blot analysis of cells
treated with DMH2, DMH1, or LDN and in combination with SB for 3 days. Only DMH2 induced the downregulation of XIAP. (e) The knockdown
of XIAP was performed using siRNA in H1299 cells and after 3 days percentage of dead cells determined. (f) Western blot analysis showing that
knockdown of XIAP decreases the expression of pTAK1. (g) H1299 cells were transiently transfected with mutant XIAP with ubiquitination sites
removed. Western blot analysis after 48 h demonstrates increased expression of pTAK1. (h) H1299 cells were transiently transfected with control
vector and mutant XIAP containing a N-terminal c-Myc epitope. Cells immediately after transfection were treated with DMSO or DMH2 for 3 days.
Western blot demonstrating that DMH2 decreased expression of wild type XIAP but not of mutant XIAP. (i) H1299 cells were stably transfected
with vector control and mutant XIAP. Cells were treated with and without DMH2 for 3 days and the percentage of cell death was determined.
DMH2 only induced cell death in the vector control cells. All experiments were performed at least 3 times. (j) Western blot analysis of stable
transfected cells treated with DMSO or DMH2 for 3 days. The bottom panel shows a shorter exposure of the panel above (n = 2)
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in benign cells, both the BMP and TGFβ signaling cas-
cades activate TAK1 in lung cancer cells. Importantly,
our studies suggest that the inhibition of both BMP and
TGFβ pathways will enhance the downregulation of
TAK1 and Id1 expression as well as having a greater
anti-tumorigenic response. TGFβ signaling predomin-
antly inhibits the transcription of Id1 through its activa-
tion of Smad2 and Smad3. Smad3, but not Smad2, has
been shown to cause a transient increase in the tran-
scription of Id1 [22]. Smad3 inhibition of the Id1 pro-
moter requires co-binding with ATF3 [21]. In the
absence of ATF3, Smad3 activates the transcription of
Id1 [21]. The increased expression of Id1 in our studies
does not appear to be from TGFβ signaling changing
from a negative to a positive transcriptional regulator of
Id1 since there was no significant change in the expres-
sion of ATF3 following the inhibition of TGFβ or BMP
signaling.
Our studies also show that in addition to inhibiting
TGFβ signaling, DMH2 potency was dependent on the
downregulation of XIAP. XIAP is an upstream regulator
of TAK1 during development. We found that XIAP was
also an upstream regulator of TAK1 in lung cancer cells.
The TGFβ signaling pathway has been shown to activate
TAK1 independently of XIAP. TGFβ receptors bind to
necrosis factor receptor-associated factor 4 (TRAF4)
[44] and TRAF6 [45] leading to the activation of TAK1.
These studies support inhibiting both the TGFβ and
BMP signaling pathways to inhibit TAK1 and its down-
stream survival pathway. Examining differences in IC50
for the BMP and TGFβ receptors, we found only DMH2
caused inhibition of BMPRII. Developmentally, both the
type I and type II BMP receptors have been shown to
stabilize the expression of XIAP [25, 26]. Our studies
suggest that inhibition of BMPRII is required to cause
significant downregulation of XIAP. TGFβ signaling has
also been shown to increase the expression of XIAP [46,
47]. Although not specifically addressed in our studies,
the inhibition the BMP type I and/or TGFβ signaling
may also have contributed to DMH2 induced downregu-
lation of XIAP.
XIAP is the most potent inhibitor of apoptosis [29].
XIAP binds and inactivates effector caspases-3 and 7
and initiator caspase-9 [48]. XIAP also functions as an
E3 ligase, inducing the degradation of caspases via the
proteasome system [48]. TAK1 is also a potent inhibitor
of cell death [28], which is mediated through its activa-
tion of NF-κB [28] and by preventing reactive oxygen
species production [49]. NF-κB inhibits cell death by
inducing the expression of cellular FLICE-like protein
(c-FLIP) and cIAPs [28]. Smac mimetic Inhibitors of
XIAP, c-IAP-1, and c-IAP-2 can induce significant cell
death in some cancer cell lines. Resistance to Smac mi-
metics has been shown to occur through a NF-κB medi-
ated upregulation of c-FLIP [50]. Knockdown of c-FLIP
together with XIAP was sufficient to induce significant
cell death in resistant cancer cell lines [50]. These stud-
ies demonstrate the importance of inhibiting NF-κB or
its downstream pathways to induce cell death following
inhibition of XIAP. Id1 has also been shown to promote
survival of cancer cells by activating NF-kappa B [51].
Overexpression of Id proteins decreased DMH2 induced
cell death of H1299 cells [16]. These studies suggest that
suppression of XIAP, TAK1, and Id proteins may be re-
quired for a BMP inhibitor like DMH2 to induce signifi-
cant death of cancer cells.
Fig. 7 DMH1 together with TGFβ inhibition induces cell death and downregulates pTAK1 that is greatest when XIAP is knocked down. BMPRII
regulates XIAP expression. a H1299 cells were treated with control siRNA and siRNA targeting XIAP and treated with DMH1 and the TGFβ
inhibitor LY2109761 (LY) (n = 3). Cells with knockdown of XIAP and treated with DMH1 and LY demonstrated the greatest percentage of cell
death. (b) Western blot analysis showing that H1299 cells with knockdown of XIAP and treated with both DMH1 and LY had the greatest
decrease in expression of pTAK1 (n = 4). (c) Western blot analysis demonstrating knockdown of BMPRII in H1299 cells with siRNA decreases the
expression of XIAP (n = 4)
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Conclusions
This study suggests a paradigm in which the BMP and
TGFβ signaling pathways regulate the survival of cancer
cells that involves both Smad dependent and independ-
ent signaling. We show that inhibition of the BMP sig-
naling cascade with small molecule inhibitors decrease
the expression of the potent inhibitors of cells death,
XIAP and TAK1 through evolutionary conserved path-
ways. We provide evidence that a small molecule recep-
tor inhibitor that targets both the BMP and TGFβ
receptors enhances the downregulation of TAK1 by pre-
venting the feedback activation of TAK1 by TGFβ sig-
naling, which occurs following the suppression BMP
signaling alone. Our studies suggest the that an inhibitor
targeting BMP and TGFβ type I and type II receptors
best inhibits anti-apoptotic pathways to induce death of
lung cancer cells. The high level of expression of BMP
proteins in cancer with little expression in normal tissue,
and the ability of BMP inhibitors to regulate several
anti-apoptotic pathways suggest that targeting the BMP
signaling cascade may provide an effective strategy for
the treatment of lung cancer.
Methods
Mice studies were approved by the Rutgers, Robert
Wood Johnson Medical School Institutional Animal
Care and Use Committee.
Plasmids
Constitutively active alk3 and alk6 constructs in
mammalian vectors were gifts from Joan Massague
(New York, New York). Constitutively active alk5 was
a gift from Fang Liu (Rutgers-New Jersey Medical
School). The Id1/luciferase promoter was a gift from
Dr. Desprez (California Pacific Medical Center). Plas-
mids pc DNA3-XIAP-Myc and pcDNA3-XIAP-Myc
K322/D28 were gifts from Guy Salvesen (Addgene
plasmid # 11833 and plasmid # 11834).
Cell culture and reagents
The A549 and H1229 lung cancer cell lines were cul-
tured in Dulbecco’s Modified Eagle’s medium
(DMEM, Sigma Aldrich, St Louis, MO, USA) with
5 % fetal bovine serum (FBS), 1 % antibiotic/antimy-
cotic, and 1 % L-glutamine [52]. The lung cancer cell
lines H157, H727, U1752, and H358, and H865 were
cultured in 90 % RPMI and 10 % FCS. The cell lines
were obtained from ATCC and from Malcolm Brock,
Johns Hopkins University.
BMP inhibitors
Dorsomorphin (compound C) was purchased from
Sigma Aldrich (St. Louis, MO) and DMH1, and LDN-
193189 (LDN) were purchased from Selleckchem
(Houston, TX.) DMH2 was synthesized at Rutgers- New
Jersey Medical School (Dave Augeri). TGFβ inhibi-
tors LY2109761 and SB-505124 were purchased from
Selleckchem and Sigma Aldrich (St. Louis, MO) re-
spectively. The Tak1 inhibitor 5Z-7-oxozeaenol was
purchased from Sigma Aldrich.
Transient gene knockdown and transfections
Select siRNA were used to target the type I BMP recep-
tors alk2, alk3, and alk6 (Life Technologies). The ID
numbers of the siRNA are: alk2 (s974), alk3 (s281), alk6
(s2042). The knockdown of the BMP receptors with
these siRNAs have been previously validated on the
H1299 cells and confirmed on the blots used in this
study [16]. Validated siRNA XIAP (S1456), siRNA
TAK1, and siRNA BMPRII were purchased from Life
Technologies. Silencer Select Negative Control siRNA
(4390843) was used to confirm specificity of each tar-
geted knockdown.
Cells were transfected with siRNA using a Nucleofec-
tor II (Amaxa Biosystems, Gaitherburg, MD) using the
manufacture’s Nucleofector kit T. Studies using cell
death assay cells were transfected with Lipofectamine
3000. A total of 30nM of siRNA was used for alk2 and
alk3 [16] and 20 nM for alk6 and 30nM for XIAP. Plas-
mid cDNA was transfected at 2.5ug.
Western blot analysis
Total cellular protein was prepared using RIPA buffer
containing a protease inhibitor cocktail and protein con-
centration was measured using the BCA assay as de-
scribed [4]. In brief, protein was analyzed by SDS-PAGE,
transferred to nitrocellulose (Schleicher and Schuell,
Keene, NH). After blocking, the blots were incubated
overnight at 4 °C with the appropriate primary antibody
in Tris-buffered saline with 1 % Tween (TBST) and 5 %
BSA. Secondary antibodies were applied for 1 h at room
temperature. Specific proteins were detected using the
enhanced chemiluminescence system (Amersham,
Arlington Heights, IL). The primary antibodies that were
used were rabbit monoclonal anti-pSmad 1/5, rabbit
monoclonal anti-pSmad2, rabbit monoclonal anti-Smad2,
rabbit monoclonal anti-pTAK1, rabbit monoclonal XIAP,
rabbit anti-monoclonal p-p65, rabbit monoclonal anti-
activated caspase-3, rabbit polyclonal anti-BMPRII, and
rabbit monoclonal anti-EGR-1 (Cell signaling Technology,
Danvers MA), Rabbit monoclonal anti-TAK1 (Invitrogen,
Grand Island NY), rabbit anti-actin, an affinity isolated
antigen specific antibody (Sigma, Saint Louis, MO), rabbit
monoclonal anti-Id1 and rabbit monoclonal anti-Id3
(Calbioreagents, San Mateo, CA), rabbit polyclonal anti-
GAPDH (Sigma, St. Louis, MO) and rabbit polyclonal
pMEK-1/2 (Cell Signaling, Danvers MA).
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Luciferase assays
H1299 cells were stably transfected with the Id1-
promoter luciferase reporter. Treated cells were lysed
with 1X luciferase lysis buffer (Promega). Samples were
added to luciferase assay substrate (Promega) and lumi-
nsescence measured by the TD-20/20 Luminometer
(Turner Designs/Turner BioSystems, Sunnyvale, CA).
Control samples included luciferase assay substrate
alone and luciferase assay substrate plus 1X reporter
lysis buffer.
Tumor xenografts
H1299 cells were stably transfected with the Id1
promoter-luciferase reporter. Five million cells were
injected subcutaneously into the flank of NCI female
nude mice. After approximately 12 days the mice were
anesthetized and the luciferase activity measured. Base-
line luciferase activity was obtained just prior to the in-
jection of inhibitors. Mice were injected IP with 150 mg/
kg luciferin-D and after a 15-min uptake period tumors
were imaged with IVIS Spectrum and analyzed using
Living Image software. Mice were injected IP with
DMSO, 3 mg/kg DMH2, or 3 mg/kg LDN and after 4 h
luciferase activity determined. Two days later, baseline
luciferase activity again determined and mice were
injected IP with DMSO, 3 mg/kg DMH2, or 3 mg/kg
LDN every 8 h for three doses and luciferase activity
was measured 4 h after the last dose. In separate animal
experiment, mice with established tumors were treated
with DMSO or 3 mg/kg DMH2 twice daily for 48 h and
luciferase activity compared to baseline. The tumors
were harvested on ice, homogenized, and placed in lysis
buffer. In a separate experiment, mice with established
tumor xenografts were injected IP with DMSO, 3 mg/kg
DMH2, or 9 mg/kg DMH2 every 12 h for 9 days and tu-
mors were then harvested.
Cell counts
Cells were plated into 6 well plates at 105 cells per well
and treated with 1 μM DMSO or antagonist for 7 days.
The cells were detached with trypsin, stained with try-
pan blue, and the number of live cells counted using a
hemocytometer.
Cell death assay
Cells were plated in 6 well plates with 106 cells per well.
Three days following treatment with inhibitor(s) and/or
transfection the adherent and floating cells were harvested
and incubated with 0.1 mg/ml of ethidium bromide. Cells
that die by necrosis or apoptosis lose membrane integrity
and take up ethidium bromide [53]. Immediately after
staining approximately 100 cells were counted and the
percentage of cells that took up ethidium bromide was
determined.
In vitro kinase IC50
The IC50 of DMH2 for alk2, alk3, alk6, alk5, BMPRII,
and TGFβ were performed at Reaction Biology Corpor-
ation (Malvern, PA). This was a 10-point assay starting
from 100 μM to 100 nM performed in duplicate. The
ATP concentration was 10 Micromolar.
Plasma protein binding
Human and mouse protein plasma binding of DMH2 was
performed using equilibrium dialysis (Sai Life Sciences
Limited, Pune India).
Pharmacokinetics
The pharmacokinetics of DMH2 was examined in maie
BALB/c mice following intravenous and oral administra-
tion (Sai Life Sciences Limited, Pune India). Three mice
at each time point were dosed with a 2 mg/kg tail vein
injection and 10 mg/kg p.o. Blood samples were taken
0.08, 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h (i.v.) and 0.25, 0.5,
1, 2, 4, 6, 8, 12, and 24 h (p.o.). Plasma half-life, clear-
ance, and volume of distribution were then determined.
Statistical analysis
The mean of the control group was compared to the mean
of each treated group using a paired student t-test assum-
ing unequal variances. Differences with p values <0 .05
were considered statistically significant.
Additional files
Additional file 1: Figure S1. DMH2 decreases Id1 expression and
growth of lung cancer cell lines in vitro. (A) Western Blot analysis of
panel of cell lines in cell culture treated with 1 μM DMH2 for 48 h
demonstrating a downregulation of Id1. (B) Cell counts of cell lines
treated with 1 μM DMH2 for 7 days. Data is depicted as percent of
vehicle control. Experiments were performed 3 times. (TIF 749 kb)
Additional file 2: Figure S2. Low doses of DMH2 increases Id1
expression in A549 cells. Western blot analysis of A549 cells in cell culture
treated with increasing doses of DMH2 for (A) 24 and (B) 48 h. Non-
specific band from the same Western blot was used as a loading control.
Experiments performed at least 3 times. (TIF 2680 kb)
Additional file 3: Figure S3. Pharmacokinetics of DMH2. (A)
Determination of DMH2 plasma concentration following IV and PO
injections demonstrates rapid clearance. (B) The unbound free fraction of
DMH2 was calculated from plasma concentration over time from IV
injection in mice assuming 98.3 % was bound to plasma proteins.
(TIF 1187 kb)
Additional file 4: Figure S4. MEK-1/2 and Src signaling do not cause
feedback activation of Id1 following inhibition of BMP signaling. (A-B)
Western blot of tumor xenografts treated with BMP inhibitors for 24 h
and 9 days. (C) Western blot analysis of H1299 cells treated with DMH2
for 24 and 48 h. (D) Western blot analysis of A549 cells treated with
DMH2 for 48 h. (E) H1299 Id1-luc cells were treated with DMH2 or
PD0325901 (PD) alone or in combination for 48 h and luciferase activity
determined. (F-G) H1299 and A549 cells were treated with DMH2 or PD
alone, or in combination and the number of live cells determined after
7 days. (E-G) Data depict the mean as the percent of control. Experiments
were performed at least 3 times. (TIF 9413 kb)
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Additional file 5: Figure S5. DMH2 is more potent than DMH1. H1299
Id-1 luc cells were treated with increasing concentrations of DMH1 or
DMH2 for 48 h and luciferase activity was determined. The data
represents the mean of at least 4 experiments. (TIF 359 kb)
Additional file 6: Figure S6. Inhibition of both BMP and TGFβ
signaling enhances growth suppression (A–D). Cell lines were treated
with DMH2 or DMH1 alone and with SB for 7 days and cell counts were
performed. The studies represent the mean of at least 3 independent
experiments. P values were determined comparing cells treated with
DMH2 and SB alone to cells treated with both inhibitors. (TIF 2411 kb)
Abbreviations
5Z: 7-oxozeaenol (5Z); AMP-kinase: adenosine monophosphate-activated pro-
tein kinase; BMP: bone morphogenetic protein; Egr-1: early growth response
protein; Id1: Inhibitor of differentiation; LDN: LDN-193189; LY: LY2109761;
MEK-1/2: mitogen-activated protein kinases; NSCLC: non-small cell lung;
SB: SB-505124; siRNA: short interfering RNA; TAB: TAK1 binding protien;
TAK1: TGFβ activated kinase; TGFβ: Transforming Growth Factor Beta;
TRAF4: necrosis factor receptor-associated factor 4; TRAF6: necrosis factor
receptor-associated factor 6; VEGF II: vascular endothelial growth factor;
XIAP: X-link inhibitor of apoptosis protein.
Competing interests
A use patent application has been submitted for the use of BMP inhibitors
for the treatment of cancer. The work in this manuscript has not been added
as supplemental data for that patent application.
Authors’ contributions
JL contributed to the conception and design, analysis and interpretation of
data, and drafted the manuscript. DA: contributed to the analysis and
interpretation of data, and performed a critical revision of the manuscript. EL
and JG performed all the experiments and analyzed the data. MG
synthesized DMH2, and contributed to analysis of the data. All authors read
and approved the final manuscript.
Authors’ information
JL is a researcher who has contributed and studied BMP in lung cancer for
the last 15 year. EL has performed the majority of the experiments on BMP.
MC is a pre-medical student who has worked in this laboratory for the last
2 years performing several of the experiments reported in this manuscript.
DA and JG are medicinal chemists who synthesized DMH2. They have
worked in field of cell signaling for over 20 years. DA collaborated and
contributed intellectually to this work from the inception of this manuscript.
Acknowledgements
We thank Neil Campbell from Preclinical imaging at the Rutgers Cancer
Institute of New Jersey for his work with luciferase experiments performed
on the tumor xenograft in nude mice tumors. This research was funded by
internal support from the Rutgers Cancer Institute of New Jersey.
Author details
1Rutgers Translational Sciences, Department of Medicinal Chemistry, School
of Pharmacy, New Brunswick, NJ, USA. 2Division of Surgical Oncology,
Rutgers Cancer Institute of New Jersey, MEB 536, One Robert Wood Johnson
Place, P.O. Box 19, New Brunswick, NJ 08903-0019, USA.
Received: 20 August 2015 Accepted: 23 March 2016
References
1. Weaver M, Yingling JM, Dunn NR, Bellusci S, Hogan BL. Bmp signaling
regulates proximal-distal differentiation of endoderm in mouse lung
development. Development. 1999;126(18):4005–15.
2. Sountoulidis A, Stavropoulos A, Giaglis S, Apostolou E, Chuva de Sousa
Lopes SM, et al. Activation of the canonical bone morphogenetic protein
(BMP) pathway during lung morphogenesis and adult lung tissue repair.
PLoS One. 2012;7(8), e41460. Epub 2012 Aug 20.
3. Langenfeld EM, Bojnowski J, Perone J, Langenfeld J. Expression of bone
morphogenetic proteins in human lung carcinomas. Ann Thorac Surg. 2005;
80(3):1028–32.
4. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld
J. The mature bone morphogenetic protein-2 is aberrantly expressed in
non-small cell lung carcinomas and stimulates tumor growth of A549 cells.
Carcinogenesis. 2003;24(9):1445–54. Epub 2003 Jun 19.
5. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates
angiogenesis in developing tumors. Mol Cancer Res. 2004;2(3):141–9.
6. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein 2
stimulation of tumor growth involves the activation of smad-1/5.
Oncogene. 2006;25(5):685–92.
7. Ye L, Mason MD, Jiang WG. Bone morphogenetic protein and bone metastasis,
implication and therapeutic potential. Front Biosci. 2011;16:865–97.
8. Le Page C, Puiffe ML, Meunier L, Zietarska M, de Ladurantaye M, Tonin PN,
et al. BMP-2 signaling in ovarian cancer and its association with poor
prognosis. J Ovarian Res. 2009;2:4.
9. Nickel J, Sebald W, Groppe JC, Mueller TD. Intricacies of BMP receptor
assembly. Cytokine Growth Factor Rev. 2009;20(5–6):367–77.
10. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily.
Science. 2002;296(5573):1646–7.
11. Katagiri T, Imada M, Yanai T, Suda T, Takahashi N, Kamijo R. Identification of
a BMP-responsive element in Id1, the gene for inhibition of myogenesis.
Genes Cells. 2002;7(9):949–60.
12. Korchynskyi O, ten Dijke P. Identification and functional characterization of
distinct critically important bone morphogenetic protein-specific response
elements in the Id1 promoter. J Biol Chem. 2002;277(7):4883–91.
13. Kurooka H, Nakahiro T, Mori K, Sano K, Yokota Y. BMP signaling is
responsible for serum-induced Id2 expression. Biochem Biophys Res
Commun. 2012;420(2):281–7. doi:10.1016/j.bbrc.2012.02.150. Epub Mar 6.
14. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O’Reilly R, et al. Id1 and
Id3 are required for neurogenesis, angiogenesis and vascularization of
tumour xenografts. Nature. 1999;401(6754):670–7.
15. Hollnagel A, Oehlmann V, Heymer J, Ruther U, Nordheim A. Id genes are
direct targets of bone morphogenetic protein induction in embryonic stem
cells. J Biol Chem. 1999;274(28):19838–45.
16. Langenfeld E, Hong CC, Lanke G, Langenfeld J. Bone morphogenetic
protein type I receptor antagonists decrease growth and induce cell death
of lung cancer cell lines. PLoS One. 2013;8(4), e61256. doi:10.1371/journal.
pone.0061256. Print 2013.
17. Swarbrick A, Roy E, Allen T, Bishop JM. Id1 cooperates with oncogenic Ras
to induce metastatic mammary carcinoma by subversion of the cellular
senescence response. Proc Natl Acad Sci U S A. 2008;105(14):5402–7. Epub
2008 Mar 31.
18. Gautschi O, Tepper CG, Purnell PR, Izumiya Y, Evans CP, Green TP, et al.
Regulation of Id1 expression by SRC: implications for targeting of the bone
morphogenetic protein pathway in cancer. Cancer Res. 2008;68(7):2250–8.
19. Tournay O, Benezra R. Transcription of the dominant-negative helix-loop-
helix protein Id1 is regulated by a protein complex containing the
immediate-early response gene Egr-1. Mol Cell Biol. 1996;16(5):2418–30.
20. Gronroos E, Kingston IJ, Ramachandran A, Randall RA, Vizan P, Hill CS.
Transforming growth factor beta inhibits bone morphogenetic protein-
induced transcription through novel phosphorylated Smad1/5-Smad3
complexes. Mol Cell Biol. 2012;32(14):2904–16. doi:10.1128/MCB.00231-12.
Epub 2012 May 21.
21. Kang Y, Chen CR, Massague J. A self-enabling TGFbeta response coupled to
stress signaling: smad engages stress response factor ATF3 for Id1
repression in epithelial cells. Mol Cell. 2003;11(4):915–26.
22. Liang YY, Brunicardi FC, Lin X. Smad3 mediates immediate early induction
of Id1 by TGF-beta. Cell Res. 2009;19(1):140–8.
23. Qi X, Li TG, Hao J, Hu J, Wang J, Simmons H, et al. BMP4 supports self-
renewal of embryonic stem cells by inhibiting mitogen-activated
protein kinase pathways. Proc Natl Acad Sci U S A. 2004;101(16):6027–
32. Epub 2004 Apr 9.
24. Wong WK, Knowles JA, Morse JH. Bone morphogenetic protein receptor
type II C-terminus interacts with c-Src: implication for a role in
pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2005;33(5):
438–46. Epub 2005 Jul 7.
25. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, et al.
XIAP, a cellular member of the inhibitor of apoptosis protein family,
links the receptors to TAB1-TAK1 in the BMP signaling pathway. Embo
J. 1999;18(1):179–87.
26. Liu Z, Shen J, Pu K, Katus HA, Ploger F, Tiefenbacher CP, et al. GDF5 and
BMP2 inhibit apoptosis via activation of BMPR2 and subsequent stabilization
Augeri et al. Molecular Cancer  (2016) 15:27 Page 15 of 16
of XIAP. Biochim Biophys Acta. 2009;1793(12):1819–27. doi:10.1016/j.bbamcr.
2009.09.012.
27. Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, et al. TAK1 is
an essential regulator of BMP signalling in cartilage. Embo J. 2009;28(14):
2028–41. doi:10.1038/emboj.2009.162. Epub Jun 18.
28. Mihaly SR, Ninomiya-Tsuji J, Morioka S. TAK1 control of cell death. Cell
Death Differ. 2014;21(11):1667–76. doi:10.1038/cdd.2014.123.
29. Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein—a critical
death resistance regulator and therapeutic target for personalized cancer
therapy. Frontiers in oncology. 2014;4:197. doi:10.3389/fonc.2014.00197.
30. Jiao G, Guo W, Ren T, Lu Q, Sun Y, Liang W, et al. BMPR2 inhibition induced
apoptosis and autophagy via destabilization of XIAP in human
chondrosarcoma cells. Cell death & disease. 2014;5, e1571. doi:10.1038/
cddis.2014.540.
31. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In vivo
structure-activity relationship study of dorsomorphin analogues identifies
selective VEGF and BMP inhibitors. ACS Chem Biol. 2010;5(2):245–53. doi:10.
1021/cb9002865.
32. Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, et al. Structure-activity
relationship study of bone morphogenetic protein (BMP) signaling
inhibitors. Bioorg Med Chem Lett. 2008;18(15):4388–92.
33. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, et
al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and
importance to inhibiting these pathways in human health. Oncotarget.
2011;2(3):135–64.
34. Shim JH, Greenblatt MB, Xie M, Schneider MD, Zou W, Zhai B, et al. TAK1 is
an essential regulator of BMP signalling in cartilage. EMBO J. 2009;28(14):
2028–41. doi:10.1038/emboj.2009.162.
35. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and
structure-activity relationships of a novel and selective bone morphogenetic
protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine
scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3
selective MLPCN probe. Bioorg Med Chem Lett. 2013;23(11):3248–52. doi:10.
1016/j.bmcl.2013.03.113. Epub Apr 11.
36. Wu J, Powell F, Larsen NA, Lai Z, Byth KF, Read J, et al. Mechanism and in
vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol. ACS Chem
Biol. 2013;8(3):643–50. doi:10.1021/cb3005897. Epub 2013 Jan 7.
37. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors
of the TGFβ and BMP pathways. Cell Signal. 2011;23(11):1831–42. doi:10.
1016/j.cellsig.2011.06.019. Epub Jun 29.
38. Yamaguchi K, Nagai S, Ninomiya-Tsuji J, Nishita M, Tamai K, Irie K, et al. XIAP,
a cellular member of the inhibitor of apoptosis protein family, links the
receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 1999;18(1):
179–87. doi:10.1093/emboj/18.1.179.
39. Shin H, Okada K, Wilkinson JC, Solomon KM, Duckett CS, Reed JC, et al.
Identification of ubiquitination sites on the X-linked inhibitor of apoptosis
protein. Biochem J. 2003;373(Pt 3):965–71. doi:10.1042/bj20030583.
40. Melisi D, Ishiyama S, Sclabas GM, Fleming JB, Xia Q, Tortora G, et al.
LY2109761, a novel transforming growth factor beta receptor type I and
type II dual inhibitor, as a therapeutic approach to suppressing pancreatic
cancer metastasis. Mol Cancer Ther. 2008;7(4):829–40. doi:10.1158/1535-
7163. mct-07-0337.
41. Heinke J, Kerber M, Rahner S, Mnich L, Lassmann S, Helbing T, et al. Bone
morphogenetic protein modulator BMPER is highly expressed in malignant
tumors and controls invasive cell behavior. Oncogene. 2012;31(24):2919–30.
doi:10.1038/onc.2011.473. Epub Oct 24.
42. Prabhu S, Ignatova A, Park ST, Sun XH. Regulation of the expression of
cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol.
1997;17(10):5888–96.
43. O’Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, et al. ID1 and
ID3 regulate the self-renewal capacity of human colon cancer-initiating cells
through p21. Cancer Cell. 2012;21(6):777–92. doi:10.1016/j.ccr.2012.04.036.
44. Zhang L, Zhou F, Garcia de Vinuesa A, de Kruijf EM, Mesker WE, Hui L, et al.
TRAF4 promotes TGF-beta receptor signaling and drives breast cancer
metastasis. Mol Cell. 2013;51(5):559–72. doi:10.1016/j.molcel.2013.07.014.
45. Sorrentino A, Thakur N, Grimsby S, Marcusson A, von Bulow V, Schuster N,
et al. The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a
receptor kinase-independent manner. Nat Cell Biol. 2008;10(10):1199–207.
doi:10.1038/ncb1780.
46. Van Themsche C, Chaudhry P, Leblanc V, Parent S, Asselin E. XIAP gene
expression and function is regulated by autocrine and paracrine TGF-beta
signaling. Mol Cancer. 2010;9:216. doi:10.1186/1476-4598-9-216.
47. Neil JR, Tian M, Schiemann WP. X-linked inhibitor of apoptosis protein and
its E3 ligase activity promote transforming growth factor-{beta}-mediated
nuclear factor-{kappa}B activation during breast cancer progression. J Biol
Chem. 2009;284(32):21209–17. doi:10.1074/jbc.M109.018374.
48. Kaufmann T, Strasser A, Jost PJ. Fas death receptor signalling: roles of Bid
and XIAP. Cell Death Differ. 2012;19(1):42–50. doi:10.1038/cdd.2011.121.
49. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens B, Zobel K,
Deshayes K, et al. cIAP1 and TAK1 protect cells from TNF-induced necrosis
by preventing RIP1/RIP3-dependent reactive oxygen species production.
Cell Death Differ. 2011;18(4):656–65. doi:10.1038/cdd.2010.138.
50. Cheung HH, St Jean M, Beug ST, Lejmi-Mrad R, LaCasse E, Baird SD, et al.
SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds.
Cell death & disease. 2011;2, e146. doi:10.1038/cddis.2011.25.
51. Peng X, Wang Y, Kolli S, Deng J, Li L, Wang Z, et al. Physical and functional
interaction between the ID1 and p65 for activation of NF-kappaB. Am J
Physiol Cell Physiol. 2012;303(3):C267–77. doi:10.1152/ajpcell.00365.2011.
52. Langenfeld EM, Kong Y, Langenfeld J. Bone morphogenetic protein-2-
induced transformation involves the activation of mammalian target of
rapamycin. Mol Cancer Res. 2005;3(12):679–84.
53. Leite M, Quinta-Costa M, Leite PS, Guimaraes JE. Critical evaluation of
techniques to detect and measure cell death—study in a model of UV
radiation of the leukaemic cell line HL60. Anal Cell Pathol. 1999;19(3–4):139–51.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Augeri et al. Molecular Cancer  (2016) 15:27 Page 16 of 16
